Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus
| Autor: | Philip Brohawn, Gabriel Robbie, Bing Yao, Micki Hultquist, Warren Greth |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Moderate to severe medicine.drug_class Immunology Anti-Inflammatory Agents Disease Monoclonal antibody Antibodies Monoclonal Humanized Human immunoglobulin 03 medical and health sciences 0302 clinical medicine Refractory Interferon Recurrence medicine Immunology and Allergy Animals Humans Lupus Erythematosus Systemic In patient Molecular Targeted Therapy skin and connective tissue diseases 030203 arthritis & rheumatology Clinical Trials as Topic business.industry Antibodies Monoclonal 030104 developmental biology Oncology Interferon Type I Sifalimumab Immunotherapy business medicine.drug Signal Transduction |
| Zdroj: | Immunotherapy. 9(1) |
| ISSN: | 1750-7448 |
| Popis: | Dysregulation of the type I interferon (IFN) system is associated with various immunologic diseases, such as systemic lupus erythematosus (SLE). Targeting this dysregulation presents an attractive approach for SLE therapy. Sifalimumab, a fully human immunoglobulin G1 κ monoclonal antibody that binds to and neutralizes most IFN-α subtypes, has been recently evaluated in a Phase IIb study in patients with moderate to severe SLE. Insights gained from earlier studies were used to inform design of the Phase IIb study, to provide a more comprehensive evaluation of sifalimumab. Sifalimumab demonstrated broad efficacy across composite and organ-specific end points, suggesting that targeting of IFN-α is a promising treatment option for SLE, particularly for those patients whose disease is refractory to current standard of care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|